EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Adjuvant-dependent protection of SARS-CoV-2 spike vaccines: comparative immunogenicity of human-applicable formulations

Zhendong Pan, Liangliang Jiang, Yingying Chen, Haoran Peng, Yangang Liu, Xu Zheng, Yanhua He, Yan Liu, Ying Wang, Xiaoyan Zhang, Zhongtian Qi, Cuiling Ding iD und 2 weitere

Journal of Virology · 2025

DOI: 10.1128/jvi.01099-25 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Virology, 2025. Verfasst von Zhendong Pan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai, China. Hauptthemen laut MEDLINE: Spike Glycoprotein, Coronavirus, COVID-19 Vaccines, SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology of the People's Republic of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although recombinant vaccines with various adjuvant systems are widely deployed in global coronavirus disease 2019 immunization, their distinct immune profiles have not been fully elucidated. In this study, we evaluated immune responses induced by four clinically validated adjuvants—aluminum hydroxide (Al), two water-in-oil emulsions (Montanide ISA720 and ISA51), and an oil-in-water emulsion (Sepivac SWE)—formulated with the prefusion-stabilized ancestral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike trimer (S-2P) in mouse models. Both S-2P:ISA720 and S-2P:ISA51 elicited potent humoral immunity, including cross-neutralizing antibodies against Omicron variants, along with robust interferon gamma-producing T-cell responses in the spleen and lung. Immunization with S-2P:ISA720 conferred complete protection against lethal challenge with the ancestral virus as well as Omicron subvariants BA.5 and BF.7. In contrast, S-2P:Al and S-2P:SWE elicited substantially weaker antibody responses, undetectable T-cell immunity, and markedly reduced protective efficacy. Prime-boost immunization with S-2P:ISA720 induced sustained peak antibody titers against both homologous SARS-CoV-2 and the Omicron BA.2 subvariant, affording complete protection for up to 17 weeks post-vaccination. While a third dose of S-2P:Al following a prime-boost regimen triggered a robust increase in antibody levels, titers declined rapidly thereafter, recapitulating the decay kinetics observed after the second dose. Both ISA720 and Al formulations exhibited age-dependent declines in antibody responses and protective efficacy. Notably, aged mice displayed markedly attenuated neuroinflammatory responses following SARS-CoV-2 challenge and significantly compromised protection after adoptive transfer of immune serum. These results underscore adjuvant-specific determinants of broad and durable immunity and reveal novel age-related constraints in vaccine-induced protection against SARS-CoV-2. IMPORTANCE Persistent viral evolution, rapid waning of vaccine-induced immunity, and the heightened vulnerability of elderly populations remain major challenges for COVID-19 vaccination strategies. In this study, we systematically assessed immune responses elicited by the ancestral spike protein formulated with four distinct adjuvants in mouse models. We demonstrate that an optimized adjuvant formulation markedly enhances the magnitude and breadth of antibody responses, potentiates T-cell immunity, and rapidly induces sustained peak antibody titers against both homologous virus and Omicron variants. Vaccine-induced antibody responses were significantly attenuated in aged mice, and furthermore, both the protective efficacy of antibodies and inflammatory cytokine responses upon viral challenge were impaired in aged animals. These results provide compelling evidence that rational adjuvant selection is critical for enabling recombinant vaccines to achieve rapid-onset, broad, and durable immune protection. Furthermore, our study offers new mechanistic insights into the reduced vaccine efficacy observed in the elderly.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spike Glycoprotein, CoronavirusCOVID-19 VaccinesSARS-CoV-2COVID-19Adjuvants, ImmunologicAdjuvants, VaccineImmunogenicity, VaccineAnimalsMiceAntibodies, ViralAntibodies, NeutralizingFemaleHumansMice, Inbred BALB CT-LymphocytesDisease Models, AnimalImmunity, Humoral

Stichwörter der Autor:innen

SARS-CoV-2adjuvantbooster immunizationcross-protectionimmunosenescencespike protein

Substanzen

Spike Glycoprotein, CoronavirusCOVID-19 VaccinesAdjuvants, ImmunologicAntibodies, Viralspike protein, SARS-CoV-2Antibodies, NeutralizingAdjuvants, Vaccine

Autor:innen und Institutionen

  • Department of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai, China.
  • Department of Microbiology and Immunology, Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Shanghai Institute of Virology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Shanghai Public Health Clinical Center & Institutes of Biomedical Sciences, Fudan University, Shanghai, China.

ORCID-Profile: Cuiling Ding, Jianqing Xu, Ping Zhao

Förderung

  • Ministry of Science and Technology of the People's Republic of China
  • National Natural Science Foundation of China

Zitieren

APA

Pan, Z., Jiang, L., Chen, Y., Peng, H., Liu, Y., Zheng, X., He, Y., Liu, Y., Wang, Y., Zhang, X., Qi, Z., Ding, C., Xu, J., & Zhao, P. (2025). Adjuvant-dependent protection of SARS-CoV-2 spike vaccines: comparative immunogenicity of human-applicable formulations. Journal of Virology. https://doi.org/10.1128/jvi.01099-25

Vancouver

Pan Z, Jiang L, Chen Y, Peng H, Liu Y, Zheng X, et al. Adjuvant-dependent protection of SARS-CoV-2 spike vaccines: comparative immunogenicity of human-applicable formulations. Journal of Virology. 2025. doi:10.1128/jvi.01099-25

BibTeX
@article{Pan2025,
  author = {Pan, Zhendong and Jiang, Liangliang and Chen, Yingying and Peng, Haoran and Liu, Yangang and Zheng, Xu and He, Yanhua and Liu, Yan and Wang, Ying and Zhang, Xiaoyan and Qi, Zhongtian and Ding, Cuiling and Xu, Jianqing and Zhao, Ping},
  title = {Adjuvant-dependent protection of SARS-CoV-2 spike vaccines: comparative immunogenicity of human-applicable formulations},
  journal = {Journal of Virology},
  year = {2025},
  doi = {10.1128/jvi.01099-25}
}
Kostenlos starten →